




RealRate

PHARMACEUTICAL 2019

Evelo Biosciences Inc.
Rank 143 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2019

Evelo Biosciences Inc.
Rank 143 of 371

The relative strengths and weaknesses of Evelo Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evelo Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 271% points. The greatest weakness of Evelo Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -88%, being 243% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	151,622
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,235
Liabilities, Non-Current	12,612
Other Assets	1,320
Other Compr. Net Income	-18
Other Expenses	0
Other Liabilities	1,071
Other Net Income	1,157
Property and Equipment	6,925
Research and Development	39,885
Revenues	0
Selling, General and Administrative Expense	18,218

Output Variable	Value in 1000 USD
Assets	159,867
Liabilities	22,918
Expenses	58,103
Stockholders Equity	136,949
Net Income	-56,946
Comprehensive Net Income	-56,955
Economic Capital Ratio	-88%

